CYP2D6*3 *5/*5 kit has been discontinued 2011

Product has been 2010 replaced by LightMix® kit CYP 2D6 *3*4 order no. 40-0305.

This kit allows to detect the CYP 2D6 allele *3, a substitution of base A4168, running a melting curve analysis. To differentiate between a PCR failure and presence of a deletion of both alleles (*5) the kits includes PPARg as a control target.

The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism. Cytochrome P450 2D6 (CYP2D6) is primarily localized in the liver and is known to metabolize 20% of commonly prescribed drugs, in particular, cardiovascular and psychotropic agents (debrisoquine, sparteine, propafenone, amitryptiline etc.).

The gene is highly polymorphic. Within the large number of identified allels CYP2D6*3, CYP2D6*4 and CYP2D6*6 show a particular medical relevance. About half of the caucasian population is affected by these not functional alleles, which result in poor metabolizer phenotype, characterized by a decreased ability to metabolize the substrates. Many differences are described for the global distribution of the allele frequency. The existence of nearly identical pseudogenes complicates the detection of the genotypes.

Melting curves for human CYP2D6*3. Wild type (wt) corresponds with CYP2D6 *1/*1, heterozygote (hetero) corresponds with CYP2D6 *1/*3 and mutant (mt) corresponds with CYP2D6 *3/*3.